WHWK — Whitehawk Therapeutics Share Price
0.000.00%
Last trade - 00:00- $67.84m
- $20.60m
- $25.98m
- 32
- 32
- 14
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.29 | ||
| Price to Tang. Book | 1.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -126.69% | ||
| Return on Equity | -80.79% | ||
| Operating Margin | -259.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15 | 1.12 | 15.22 | 24.35 | 25.98 | 33.33 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 16th, 2007
- Public Since
- June 26th, 2018
- No. of Shareholders
- 81
- No. of Employees
- 40
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 46,784,618
- Address
- 2 Headquarters Plaza, MORRISTOWN, 07960
- Web
- https://ir.whitehawktx.com/
- Phone
- +1 5513212234
- Contact
- Scott Giacobello
- Auditors
- BDO USA, P.C.
Upcoming Events for WHWK
Aadi Bioscience Inc Annual Shareholders Meeting
Q2 2025 Aadi Bioscience Inc Earnings Release
Similar to WHWK
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Whitehawk Therapeutics share price?
As of Today at 24:06 UTC, shares in Whitehawk Therapeutics are trading at $1.45. This share price information is delayed by 15 minutes.
How has the Whitehawk Therapeutics share price performed this year?
Shares in Whitehawk Therapeutics last closed at $1.45 and the price had moved by -13.69% over the past 365 days. In terms of relative price strength the Whitehawk Therapeutics share price has underperformed the S&P500 Index by -20.33% over the past year.
What are the analyst and broker recommendations for Whitehawk Therapeutics?
The overall consensus recommendation for Whitehawk Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Whitehawk Therapeutics dividend yield?
Whitehawk Therapeutics does not currently pay a dividend.
Does Whitehawk Therapeutics pay a dividend?
Whitehawk Therapeutics does not currently pay a dividend.
When does Whitehawk Therapeutics next pay dividends?
Whitehawk Therapeutics does not currently pay a dividend.
How do I buy Whitehawk Therapeutics shares?
To buy shares in Whitehawk Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Whitehawk Therapeutics?
As of the previous close price of $1.45, shares in Whitehawk Therapeutics had a market capitalisation of $67.84m.
Where are Whitehawk Therapeutics shares listed?
Here are the trading details for Whitehawk Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: WHWK
What kind of share is Whitehawk Therapeutics?
Based on an overall assessment of its quality, value and momentum Whitehawk Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Whitehawk Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Whitehawk Therapeutics is $2.00. That is 37.93% above the last closing price of $1.45.
Analysts covering Whitehawk Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.69 for the next financial year.
Find out moreWhat is the trend in the Whitehawk Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Whitehawk Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -23.97%.
As of the last closing price of $1.45, shares in Whitehawk Therapeutics were trading -31.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Whitehawk Therapeutics PE Ratio?
The Whitehawk Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Whitehawk Therapeutics?
We do not have data on Whitehawk Therapeutics' directors